News

Neuren intends to submit applications to the US Food and Drug Administration (FDA) for both Orphan Drug and Breakthrough Therapy designation. Neuren expects to meet with the FDA

Capstone has been created through the integration of H.I.G. portfolio companies Integrity Nutraceuticals in Spring Hill, TN and Cornerstone Research & Development in Ogden, UT. Capstone will compete

Rociletinib is the Company’s novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in

The transaction was announced on September 29, 2014 and included upfront consideration of $600 million in cash and 3,209,971 shares of AMAG common stock, and additional contingent consideration

Irenas of the United States District Court for the District of New Jersey in the patent infringement lawsuit filed by Horizon against Watson Laboratories, Inc. for an Abbreviated

Severe aplastic anaemia is a rare disorder in which the bone marrow fails to make enough new blood cells. Currently, there are no approved therapies available for SAA

Following approval for the IND application, the company will conduct a Phase I/II trial of ADXS-HPV alone or in combination with MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736,

Ophthotech now has exclusive license to investigate the potential of AVEO’s tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye. As part of

Currently, the company is conducting an international, randomized Phase III trial of TH-302 in these patients in partnership with the Sarcoma Alliance for Research through Collaboration (SARC) and